Article (Scientific journals)
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
Schettini, Francesco; Sobhani, Navid; Ianza, Anna et al.
2020In Breast Cancer Research and Treatment, 184 (2), p. 421-431
Peer Reviewed verified by ORBi
 

Files


Full Text
Immune system and angiogenesis-related potential surrogate biomarkers... - article GJ.pdf
Publisher postprint (4.76 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Biomarker; Breast cancer; Everolimus; Hormone receptors; Immunomodulation; mTOR; oncology
Abstract :
[en] PURPOSE: mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of response is available. Following evidences from other solid tumors, we aimed to assess the association between treatment-associated immune system features and everolimus activity. METHODS: We retrospectively explored a correlation with the therapeutic activity of everolimus and tumor-associated immune pathways with ingenuity pathway analysis (IPA), neutrophil-to-lymphocyte ratio (NLR), circulating lymphocytes, and endothelial cells (CECs) in 3 different HR+ mBC studies, including the BALLET phase IIIb study. RESULTS: The circulating levels of CD3(+)/CD8(+), CD3(+)/CD4(+), and overall T lymphocytes were higher in responders versus non-responders at baseline (p = 0.017, p < 0.001, p = 0.034) and after treatment (p = 0.01, p = 0.003, p = 0.023). Reduced CECs, a tumor neoangiogenesis marker, were observed in responders after treatment (p < 0.001). Patients with low NLR (≤ 4.4) showed a better progression-free survival compared to patients with high NLR (> 4.4) (p = 0.01). IPA showed that the majority of immunity-related genes were found upregulated in responders compared to non-responders before treatment, but not after. CONCLUSIONS: Lymphocytes subpopulations, CECs and NLR could be interesting biomarkers predictive of response to everolimus-based regimens, potentially useful in daily clinical practice to select/monitor everolimus-based treatment in mBC. Further studies to confirm such hypotheses are warranted.
Disciplines :
Oncology
Author, co-author :
Schettini, Francesco
Sobhani, Navid
Ianza, Anna
Triulzi, Tiziana
Molteni, Alfredo
Lazzari, Maria Chiara
Strina, Carla
Milani, Manuela
Corona, Silvia Paola
Sirico, Marianna
Bernocchi, Ottavia
Giudici, Fabiola
Cappelletti, Maria Rosaria
Ciruelos, Eva
Jerusalem, Guy  ;  Université de Liège - ULiège > Département des sciences cliniques > Oncologie
Loi, Sherine
Fox, Stephen B.
Generali, Daniele
More authors (8 more) Less
Language :
English
Title :
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
Publication date :
2020
Journal title :
Breast Cancer Research and Treatment
ISSN :
0167-6806
eISSN :
1573-7217
Publisher :
Kluwer Academic Publishers, Netherlands
Volume :
184
Issue :
2
Pages :
421-431
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 10 November 2020

Statistics


Number of views
24 (2 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
8
Scopus citations®
without self-citations
6
OpenCitations
 
7

Bibliography


Similar publications



Contact ORBi